Myoclonic jerks complicating treatment of acute promyelocytic leukemia: case report and literature review

Blood Adv. 2019 Jun 25;3(12):1854-1857. doi: 10.1182/bloodadvances.2019000249.

Abstract

  1. Myoclonic jerks and inattentiveness may be rare neurologic complications of ATO toxicity.

  2. Clinicians must be aware of this rare toxicity given that the ATO and ATRA combination is now standard-of-care treatment of low-risk APL.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Agents / toxicity*
  • Arsenic Poisoning / diagnosis
  • Arsenic Trioxide / administration & dosage
  • Arsenic Trioxide / therapeutic use
  • Arsenic Trioxide / toxicity*
  • Drug Therapy, Combination / adverse effects*
  • Drug Therapy, Combination / methods
  • Female
  • Humans
  • Idarubicin / administration & dosage
  • Idarubicin / therapeutic use
  • Leukemia, Promyelocytic, Acute / drug therapy*
  • Leukemia, Promyelocytic, Acute / pathology
  • Myoclonus / chemically induced*
  • Remission Induction
  • Steroids / administration & dosage
  • Steroids / therapeutic use
  • Topoisomerase II Inhibitors / administration & dosage
  • Topoisomerase II Inhibitors / therapeutic use
  • Treatment Outcome
  • Tretinoin / administration & dosage
  • Tretinoin / analogs & derivatives
  • Tretinoin / therapeutic use
  • Withholding Treatment

Substances

  • Antineoplastic Agents
  • EA-4 (ATRA steroidal analog)
  • Steroids
  • Topoisomerase II Inhibitors
  • Tretinoin
  • Arsenic Trioxide
  • Idarubicin